Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Genome-wide association study of varenicline-aided smoking cessation.
Nicotine Tob Res
January 2025
Department of Population Health Sciences, University of Leicester, Leicester, UK.
Introduction: Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist with the highest therapeutic efficacy of any pharmacological smoking cessation aid and a 12-month cessation rate of 26%. Genetic variation may be associated with varenicline response, but to date no genome-wide association studies of varenicline response have been published.
Methods: In this study, we investigated the genetic contribution to varenicline effectiveness using two electronic health record-derived phenotypes.
Management of Anomalous Left Vertebral Artery During Open Total Arch Replacement.
Ann Thorac Surg Short Rep
December 2024
Division of Cardiac Surgery, Department of Surgery, Northwestern University Feinberg School Medicine, Chicago, Illinois.
Background: An anomalous left vertebral artery (aLVA) can complicate aortic arch surgery. We examined the safety of various aLVA revascularization strategies during open total arch replacement.
Methods: We retrospectively evaluated 92 patients undergoing total arch replacement from January 2018 to May 2023 and identified 11 patients with aLVA.
Pregnancy among thyroid cancer survivors: do thyroidectomy and radioactive iodine matter?
Postgrad Med J
January 2025
Institute of Public Health, College of Medicine, National Yang Ming Chiao Tung University, Yang Ming Campus, No. 155, Sec. 2, Linong Street, Beitou District, Taipei 11217, Taiwan.
Background: Thyroid cancer primarily affects young women and raises concerns about future fertility due to treatments of thyroidectomy and radioactive iodine (RAI) therapy. This study investigated the effects of these treatments on pregnancy probability in young female patients post-diagnosis.
Methods: A nationwide, population-based study using data from Taiwan's National Health Insurance Research Database (2000-2017) examined pregnancy likelihood in women ≤45 years with thyroid cancer.
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation.
Mol Metab
January 2025
Section of Endocrinology and Investigative Medicine, Imperial College London, United Kingdom. Electronic address:
Objective: There is renewed interest in targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) for treatment of obesity and type 2 diabetes. G-protein coupled receptor desensitisation is suggested to reduce the long-term efficacy of glucagon-like-peptide 1 receptor (GLP-1R) agonists and may similarly affect the efficacy of GIPR agonists. We explored the extent of pancreatic GIPR functional desensitisation with sustained agonist exposure.
View Article and Find Full Text PDFEnhanced prediction of partial nitrification-anammox process in wastewater treatment by developing an attention-based deep learning network.
J Environ Manage
January 2025
School of Artificial Intelligence, Xidian University, No. 2 South Taibai Road, Xi'an, Shaanxi, 710071, China.
In the process of partial nitrification and anaerobic ammonia oxidation (anammox) for nitrogen removal, the process offers simple metabolic pathways, low operating costs, and high nitrogenous loading rates. However, since the partial nitrification-anammox (PN-anammox) process combines partial nitrification and anammox reactions within the same reactor, strict control of dissolved oxygen (DO) is essential. Additionally, assessing treatment performance through chemical measurement involves time lag, making it challenging to recover the biological process when issue arise, especially in the PN-anammox process, where strict DO control and the sensitivity of anammox bacteria to conditions and substrates demand timely intervention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!